New US Food and Drug Administration labeling on Cytotec (Misoprostol) use and pregnancy

被引：0
|
作者：
不详
机构：
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS | 2003年 / 82卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
On April 17, 2002, the U.S. Food and Drug Administration approved a new label for the use of Cytotec (misoprostol) during pregnancy. The new labeling does not contain claims regarding the efficacy and/or safety of Cytotec when it is used for cervical ripening for the induction of labor nor does it stipulate doses or dosing intervals. Therefore, the Committee on Obstetric Practice reminds Fellows that this agent should be used as previously recommended.
引用
收藏
页码：137 / 138
页数：2
相关论文
共 50 条
  • [1] The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule
    Brucker, Mary C.
    King, Tekoa L.
    [J]. JOURNAL OF MIDWIFERY & WOMENS HEALTH, 2017, 62 (03) : 308 - 316
  • [2] The new US Food and Drug Administration pregnancy and lactation labeling rules: Their impact on clinical practice
    Danesh, Melissa J.
    Murase, Jenny E.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (02) : 310 - 311
  • [3] Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
    Feldman, Daniel
    Avorn, Jerry
    Kesselheim, Aaron S.
    [J]. JAMA NETWORK OPEN, 2022, 5 (04) : E227958
  • [4] Integrating New Effectiveness Data Into US Food and Drug Administration-Approved Drug Labeling
    Gyawali, Bishal
    Darrow, Jonathan J.
    Kesselheim, Aaron S.
    [J]. JAMA INTERNAL MEDICINE, 2021, 181 (07) : 897 - 898
  • [5] Introduction to the new prescription drug labeling by the Food and Drug Administration
    Lal, Renu
    Kremzner, Mary
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (23) : 2488 - 2494
  • [6] FOOD AND DRUG ADMINISTRATION AND LABELING
    JOHNSON, OC
    [J]. JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 1974, 64 (05) : 471 - 475
  • [7] Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US
    Vaduganathan, Muthiah
    Claggett, Brian L.
    Greene, Stephen J.
    Aggarwal, Rahul
    Bhatt, Ankeet S.
    McMurray, John J. V.
    Fonarow, Gregg C.
    Solomon, Scott D.
    [J]. JAMA CARDIOLOGY, 2021, 6 (12) : 1415 - 1423
  • [8] Women's Health, Pregnancy, and the US Food and Drug Administration
    Gee, Rebekah E.
    Wood, Susan F.
    Schubert, Kathryn G.
    [J]. OBSTETRICS AND GYNECOLOGY, 2014, 123 (01): : 161 - 165
  • [9] The Influence of the Food and Drug Administration Pregnancy and Lactation Labeling Rule on Drug Information Resources
    Harris, John Brock
    Holmes, Amy P.
    Eiland, Lea S.
    [J]. ANNALS OF PHARMACOTHERAPY, 2021, 55 (04) : 459 - 465
  • [10] Knowledge of the new Food and Drug Administration pregnancy and lactation labeling rule (PLLR) among physicians and pharmacists
    Alem, Ghada
    Maneno, Mary K.
    Daftary, Monika
    Wingate, La'Marcus
    Ettienne, Earl
    Anyiwo, Adaobi
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 384 - 384
12345